These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 30936679)
1. High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology. Buzdin A; Sorokin M; Poddubskaya E; Borisov N Cancer Inform; 2019; 18():1176935119838844. PubMed ID: 30936679 [TBL] [Abstract][Full Text] [Related]
2. FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier. Tkachev V; Sorokin M; Mescheryakov A; Simonov A; Garazha A; Buzdin A; Muchnik I; Borisov N Front Genet; 2018; 9():717. PubMed ID: 30697229 [TBL] [Abstract][Full Text] [Related]
3. Flexible Data Trimming Improves Performance of Global Machine Learning Methods in Omics-Based Personalized Oncology. Tkachev V; Sorokin M; Borisov C; Garazha A; Buzdin A; Borisov N Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979006 [TBL] [Abstract][Full Text] [Related]
4. Shambhala-2: A Protocol for Uniformly Shaped Harmonization of Gene Expression Profiles of Various Formats. Borisov N; Sorokin M; Zolotovskaya M; Borisov C; Buzdin A Curr Protoc; 2022 May; 2(5):e444. PubMed ID: 35617464 [TBL] [Abstract][Full Text] [Related]
5. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs. Buzdin A; Sorokin M; Garazha A; Sekacheva M; Kim E; Zhukov N; Wang Y; Li X; Kar S; Hartmann C; Samii A; Giese A; Borisov N Semin Cancer Biol; 2018 Dec; 53():110-124. PubMed ID: 29935311 [TBL] [Abstract][Full Text] [Related]
6. Shambhala: a platform-agnostic data harmonizer for gene expression data. Borisov N; Shabalina I; Tkachev V; Sorokin M; Garazha A; Pulin A; Eremin II; Buzdin A BMC Bioinformatics; 2019 Feb; 20(1):66. PubMed ID: 30727942 [TBL] [Abstract][Full Text] [Related]
7. Uniformly shaped harmonization combines human transcriptomic data from different platforms while retaining their biological properties and differential gene expression patterns. Borisov N; Tkachev V; Simonov A; Sorokin M; Kim E; Kuzmin D; Karademir-Yilmaz B; Buzdin A Front Mol Biosci; 2023; 10():1237129. PubMed ID: 37745690 [No Abstract] [Full Text] [Related]
8. Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs. Venkova L; Aliper A; Suntsova M; Kholodenko R; Shepelin D; Borisov N; Malakhova G; Vasilov R; Roumiantsev S; Zhavoronkov A; Buzdin A Oncotarget; 2015 Sep; 6(29):27227-38. PubMed ID: 26317900 [TBL] [Abstract][Full Text] [Related]
10. Using proteomic and transcriptomic data to assess activation of intracellular molecular pathways. Buzdin A; Tkachev V; Zolotovskaia M; Garazha A; Moshkovskii S; Borisov N; Gaifullin N; Sorokin M; Suntsova M Adv Protein Chem Struct Biol; 2021; 127():1-53. PubMed ID: 34340765 [TBL] [Abstract][Full Text] [Related]
11. Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers. Zolotovskaia MA; Sorokin MI; Roumiantsev SA; Borisov NM; Buzdin AA Front Oncol; 2018; 8():658. PubMed ID: 30662873 [TBL] [Abstract][Full Text] [Related]
12. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation. Mashima T; Ushijima M; Matsuura M; Tsukahara S; Kunimasa K; Furuno A; Saito S; Kitamura M; Soma-Nagae T; Seimiya H; Dan S; Yamori T; Tomida A Cancer Sci; 2015 Jul; 106(7):909-20. PubMed ID: 25911996 [TBL] [Abstract][Full Text] [Related]
14. GeneGazer: A Toolkit Integrating Two Pipelines for Personalized Profiling and Biosignature Identification. Luo JD; Chang YJ; Chang CM; You JF; Wei PL; Chiou CC Cancer Genomics Proteomics; 2016; 13(2):141-50. PubMed ID: 26912804 [TBL] [Abstract][Full Text] [Related]
16. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077 [TBL] [Abstract][Full Text] [Related]
17. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154 [TBL] [Abstract][Full Text] [Related]
18. Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Zolotovskaia MA; Sorokin MI; Emelianova AA; Borisov NM; Kuzmin DV; Borger P; Garazha AV; Buzdin AA Front Pharmacol; 2019; 10():1. PubMed ID: 30728774 [TBL] [Abstract][Full Text] [Related]
19. A Transcriptional Program for Detecting TGFβ-Induced EMT in Cancer. Foroutan M; Cursons J; Hediyeh-Zadeh S; Thompson EW; Davis MJ Mol Cancer Res; 2017 May; 15(5):619-631. PubMed ID: 28119430 [TBL] [Abstract][Full Text] [Related]